BC
CYTK icon

BIT Capital’s Cytokinetics CYTK Stock Holding History

BIT Capital’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-1,254
Closed -$68.9K – 119
2025
Q3 		$68.9K Hold
1,254
– – ﹤0.01% 95
2025
Q2 		$41.4K Buy
+1,254
New +$43.6K ﹤0.01% 89
2025
Q1 		– Sell
-19,283
Closed -$907K – 123
2024
Q4 		$907K Buy
+19,283
New +$1M 0.07% 74
2024
Q2 		– Sell
-30,144
Closed -$2.11M – 112
2024
Q1 		$2.11M Buy
+30,144
New +$2.33M 0.16% 64

Other funds holding CYTK

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

BIT Capital's CYTK Position: Q4 2025 in Review

BIT Capital sold out of Cytokinetics (CYTK) in Q4 2025, closing a stake of 1,254 shares — an estimated $68.9K sold.

BIT Capital first reported a position in CYTK in Q1 2024 and held it in 4 quarters. The position peaked at $2.11M in Q1 2024. 430 funds tracked by Wall St. Rank hold CYTK as of Q4 2025.

  • BIT Capital reported no remaining Cytokinetics position as of Q4 2025 after selling out during the quarter.
  • BIT Capital sold 1,254 Cytokinetics shares in Q4 2025, an estimated $68.9K.
  • BIT Capital first reported a position in Cytokinetics in Q1 2024 and held it in 4 quarters.
  • BIT Capital's Cytokinetics position peaked at $2.11M in Q1 2024.
  • 430 funds tracked by Wall St. Rank held Cytokinetics as of Q4 2025.

Based on BIT Capital's 13F filing for Q4 2025, filed 11 Feb 2026.